Gastrointestinal side effects of chemotherapy are an under-recognized clinical problem, leading to dose reduction, delays and cessation of treatment, presenting a constant challenge for efficient and tolerated anti-cancer treatment. We have found that oxaliplatin treatment results in intestinal dysfunction, oxidative stress and loss of enteric neurons. BGP-15 is a novel cytoprotective compound with potential HSP72 co-inducing and PARP inhibiting properties. In this study, we investigated the potential of BGP-15 to alleviate oxaliplatin-induced enteric neuropathy and intestinal dysfunction.
Introduction
Oxaliplatin is a third-generation platinum-based drug with a high clinical efficacy for many tumour cell lines. It is usually administered together with 5-fluorouracil and leucovorin (FOLFOX) and is currently a leading treatment for gastrointestinal cancers including colorectal cancer (CRC) (Liang et al., 2010; Ziauddin et al., 2010) . Oxaliplatin exerts its cytotoxic effects via formation of platinum-DNA adducts that trigger immobilization of the mitotic cell cycle and stimulate apoptosis of dividing cells (Graham et al., 2000; Goodisman et al., 2006) . Although oxaliplatin is apparently less toxic for the auditory, haematological and renal systems at clinically recommended doses, than its predecessors, cisplatin and carboplatin (Raymond et al., 1998) , its effective administration is hindered by the onset of severe peripheral neuropathy and gastrointestinal dysfunction (Quasthoff and Hartung, 2002; Verstappen et al., 2003; Lehky et al., 2004; O'Dwyer et al., 2007; Wang et al., 2007; Brouwers et al., 2009; Baek et al., 2010; Park et al., 2011) .
Chemotherapy-induced gastrointestinal dysfunction is a significantly overlooked contributor to dose reduction and delay, presenting a constant challenge for tolerable and efficient cancer treatment (Verstappen et al., 2003; McQuade et al., 2014) . Around 40% of patients receiving standard dose chemotherapy and nearly all patients receiving high dose chemotherapy exhibit pain, ulceration, bloating, vomiting, diarrhoea and/or constipation over the course of treatment (Muss and Bynum, 2012; McQuade et al., 2014) . Platinumbased agents, in particular, are linked to a heightened incidence of gastrointestinal side effects with some studies reporting that up to 90% of patients experience vomiting, nausea, diarrhoea and/or constipation during treatment (Sharma et al., 2005) . Combination regimens including platinum-based chemotherapeutics increase the incidence of chronic diarrhoea and/or constipation which can persist for up to 10 years after the treatment has been ceased (Denlinger and Barsevick, 2009) and are linked to treatment-related death (Souglakos et al., 2006) .
Gastrointestinal side effects of anti-cancer therapy have been associated with mucosal damage (Keefe et al., 2000; Duncan and Grant, 2003; Logan et al., 2008 Logan et al., , 2009 ), but gastrointestinal dysfunction persists beyond the effective repair of the mucosal damage. This suggests that other regulatory systems, such as the enteric nervous system (ENS), are also damaged. Gastrointestinal functions are controlled by the ENS embedded in the wall of the gastrointestinal tract (Furness, 2012) . To date, few studies have investigated the effects of platinum-based chemotherapeutic agents on enteric neurons in animal models (Vera et al., 2011; Wafai et al., 2013; McQuade et al., 2016b) . These studies reported significant reductions in the number of neurons alongside heightened proportion of neuronal NOS (nNOS) immunoreactive neurons and oxidative stress in the myenteric and submucosal plexus following in vivo treatment with cisplatin (Vera et al., 2011) and oxaliplatin (Wafai et al., 2013; McQuade et al., 2016b) . These changes in the ENS are correlated with inhibition of gastrointestinal transit and colonic propulsion in cisplatin (Vera et al., 2011) and oxaliplatintreated animals (McQuade et al., 2016b; Wafai et al., 2013) leading to symptoms of constipation or diarrhoea.
Identifying drugs that effectively prevent the toxic complications of chemotherapies is imperative to improve the efficacy of anti-cancer treatment and patient quality of life. BGP-15 is a pharmacological modulator of the cytoprotective response to stress, acting as a PARP-1 inhibitor (Sarszegi et al., 2012) , heat shock protein (HSP) co-inducer (Ciocca et al., 1993; Costa et al., 1997) and mild antioxidant (Racz et al., 2002) in a variety of tissues. In rats, it appears to have neuroprotective properties in cisplatin-and taxol-induced peripheral sensory neuropathy (Bardos et al., 2003) . Many studies have shown that neutralization of ROS and pharmacological inhibition or genetic inactivation of PARP is therapeutically effective in a wide range of cardiovascular, inflammatory, vascular and neurodegenerative diseases, by protecting against cell death (Pacher et al., 2007) . Overactivation of PARP-1 and downstream products resulting in cellular energy (ATP) depletion have been identified following application of oxaliplatin in SGC-7901 human gastric cancer cells (Wu et al., 2015) , while PARP-1 inhibiting agents have been found to attenuate oxaliplatin-induced painful neuropathy (Ta et al., 2013) . Similarly, increased expression of HSPs is associated with improved symptoms of peripheral neuropathy in diabetic and chronic constriction injury of sciatic nerve in rats (Chen et al., 2012 (Chen et al., , 2013 . Collectively, these data suggested that BGP-15 was a potential therapeutic treatment for oxaliplatin-induced neurological side effects.
In this study, we tested if long-term in vivo BGP-15 cotreatment attenuated oxidative stress, enteric neuropathy and intestinal dysfunction induced by oxaliplatin treatment in mice.
Methods

Animals
All animal care and experimental procedures were approved by the Victoria University Animal Experimentation Ethics Committee and performed in accordance with the guidelines of the National Health and Medical Research Council (NHMRC) Australian Code of Practice for the Care and Use of Animals for Scientific Purposes. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . Male Balb/c mice aged 6-8 weeks (18-25 g) supplied from the Animal Resources Centre (Perth, Australia) were used for the experiments. Mice had free access to food and water and were kept under a 12 h light/dark cycle in a well-ventilated room at an approximate temperature of 22°C. Mice acclimatized for a minimum of 5 days prior to the commencement of in vivo i.p. injections. A total of 60 mice were used for this study. 
Treatment protocols
Assessment of mitochondrial superoxide production
MitoSOX ™ Red M36008 (Invitrogen, Mount Waverley, VIC, Australia) was used to visualize mitochondrially derived superoxide in whole-mount preparations of submucosal and myenteric ganglia of the colon, as previously described (McQuade et al., 2016b) . Freshly excised distal colon preparations were dissected to expose submucosal and myenteric ganglia. Preparations were incubated in oxygenated physiological saline with MitoSOX ™ Red M36008 (5 μM) in a gently shaking incubator Unimax 1010 (Heidolph Instruments, Schwabach, Germany) at a constant temperature of 37°C for 40 min. Tissues were washed (2 × 30 min) with oxygenated physiological saline (composition in mM: NaCl 118, KCl 4.6, CaCl 2 3.5, MgSO 4 1.2, NaH 2 PO 4 1, NaHCO 3 25, Dglucose 11; bubbled with 95%O 2 and 5% CO 2 ) and fixed in 4% paraformaldehyde overnight at 4°C. The following day, tissues were washed (2 × 30 min) with physiological saline and mounted on glass slides with DAKO fluorescent mounting medium for imaging under a Nikon Eclipse Ti laser scanning microscope (Nikon, Tokyo, Japan). All images were captured using identical acquisition exposure-time conditions, calibrated to standardized minimum baseline fluorescence and converted to binary. Changes in fluorescence from baseline were measured in arbitrary units (arb. units) using Image J software (NIH, Bethesda, MD, USA). The corrected total fluorescence was calculated in 32 5 × 5 μm 2 boxes within myenteric ganglia from each preparation to exclude fluorescence outside the ganglia as previously described (Burgess et al., 2010; McQuade et al., 2016b) .
Mitochondrial membrane potential assay
Mitochondrial membrane potential changes in cells may be detected with the use of cationic, lipophilic JC-10 dye. In normal cells, JC-10 concentrates in the mitochondrial matrix where it forms red fluorescent aggregates (JC aggregates). In contrast, apoptotic cells stain in green fluorescent colour (JC monomeric form) due to the JC-10-labelled release of cytochrome c diffusing out of the mitochondria as a result of mitochondrial depolarization and increased permeability. JC-10 fluorescent mitochondrial membrane potential microplate assay kit (Abcam, Cambridge, MA, USA) was used to detect mitochondrial membrane potential changes and the release of cytochrome c from damaged mitochondria in the myenteric ganglia of the distal colon, as previously described (McQuade et al., 2016b) . Freshly excised distal colon preparations from sham and oxaliplatin-treated mice were bathed in oxygenated physiological saline and dissected to expose the myenteric ganglia. Immediately following dissection, preparations were incubated for 20 min with 500 μL of JC-10 dye solution (buffer A) with gentle agitation (Unimax 1010) at a constant temperature of 37°C. After 20 min, 500 μL of buffer B solution was added to tissue preparations and allowed to incubate for a further 20 min in the same conditions. Immediately following the final incubation, tissues were mounted on glass slides with DAKO fluorescent mounting medium for imaging under a Nikon Eclipse Ti laser scanning microscope. All images were captured at identical acquisition exposure-time conditions, calibrated to standardized minimum baseline fluorescence and converted to binary. Changes in fluorescence from baseline were measured in arbitrary units (arb. units) using Image J software. The corrected total fluorescence was calculated in 32 5 × 5μm 2 boxes within myenteric ganglia from each preparation to exclude fluorescence outside the ganglia (McQuade et al., 2016b) .
Histology
The colon was excised and placed in a 10% formalin solution overnight and then transferred into 70% ethanol the following day. Paraffin-embedded colon sections were cut (5 μm) and deparaffinized, cleared and rehydrated in graded ethanol concentrations. To examine the morphological changes to the colon, standard haematoxylin and eosin staining protocol was followed (McQuade et al., 2016b) . Ten randomly selected sections per preparation were analysed and scored on the following parameters: changes in crypt architecture (0-5), reduction in crypt length (0-5), mucosal ulceration (0-5) and immune cell infiltration (0-5) (total possible score 20) (Rahman et al., 2016) . All images were analysed blindly.
Immunohistochemistry in whole-mount preparations
Distal colon segments (length 2-3 cm) were placed in oxygenated PBS (pH 7.2) containing nicardipine (3 μM) for 20 min to inhibit smooth muscle contractions. Samples were dissected along the mesenteric border, cleared of their contents, maximally stretched and the mucosa was removed to expose the myenteric plexus attached to the longitudinal muscle layer. Tissues were fixed with Zamboni's fixative (2% formaldehyde, 0.2% picric acid) overnight at 4°C. Preparations were cleared of fixative by washing 3 × 10 min with DMSO followed by 3 × 10 min washes with PBS. Fixed tissues were stored at 4°C in PBS for a maximum of 5 days. Whole-mount preparations were incubated with 10% normal donkey serum (Chemicon, Temecula, CA, USA) for 1 h at room temperature. Tissues were then washed (2 × 5 min) with PBS and incubated with primary antibodies against β-tubulin III (βTubIII) (chicken, 1:1000, Abcam), nNOS (goat, 1:500, Abcam) and choline acetyl transferase (ChAT; goat, 1:500, Abcam) overnight at 4°C. Tissues were then washed in PBS (3 × 10 min) before incubation with species-specific secondary antibodies labelled with different fluorophores: donkey anti-chicken Alexa 594 (1:200, Jackson Immuno research Laboratories, West Grove, PA, USA) and donkey antigoat Alexa 488 (1:200, Jackson Immuno research Laboratories) for 2 h at room temperature. The preparations were given 3 × 10 min final washes in PBS and then mounted on glass slides using fluorescent mounting medium (DAKO, North Sydney, NSW, Australia). From each preparation, eight randomly chosen images (total area 2 mm 2 ) were captured with a 20× objective and processed using NIS Elements software (Nikon). The number of βTubIII and nNOS immunoreactive neurons was quantified in the myenteric ganglia of each preparation. Quantitative analyses were conducted blindly.
Immunohistochemistry in cross sections
Colon samples were cut open along the mesenteric border, cleared of their contents and pinned mucosa up without stretching (n = 5 mice per group). Tissues were fixed with Zamboni's fixative overnight at 4°C. Preparations were cleared of fixative by washing 3 × 10 min with DMSO (Sigma-Aldrich) followed by 3 × 10 min washes with PBS. After washing, tissues were embedded in 100% OCT and frozen using liquid nitrogen and isopentane and stored at À80°C. Tissues were cut (20 μm sections) using a Leica CM1950 cryostat (Leica Biosystems, Nussloch, Germany), adhered to slides and allowed to rest for 30 min at room temperature before processing. Cross-section preparations were incubated with 10% normal donkey serum (Chemicon) for 1 h at room temperature. Tissues were then washed (2 × 5 min) with PBS and incubated with primary antibodies against PARP-1 and PARP-2 (mouse, 1:100, Sapphire Bioscience, NSW, Australia) overnight at 4°C. Sections were then washed in PBS (3 × 10 min) before incubation with secondary antibodies labelled with fluorophore donkey anti-mouse Alexa 488 (1:200, Jackson Immunoresearch Laboratories) for 2 h at room temperature. The sections were given 3 × 10 min final washes in PBS and then cover slipped using fluorescence mounting medium (DAKO). From each preparation, four randomly chosen images (total area 1 mm 2 ) were captured with a 20× objective and processed using NIS Elements software (Nikon). The number of PARP-1 and PARP-2 immunoreactive cells was quantified in each preparation. Quantitative analyses were conducted blindly.
Imaging
Three dimensional (z-series) images of whole-mount preparations were taken using a Nikon Eclipse Ti laser scanning microscope (Nikon). Fluorophores were visualized using excitation filters for Alexa 594 Red (excitation wavelength 559 nm), Alexa 488 (excitation wavelength 473 nm) and Alexa 405 (excitation wavelength 405 nm). Z-series images were taken at a step size of 1.75 μm (1600 × 1200 pixels).
Gastrointestinal transit
Gastrointestinal transit was studied by X-ray prior to the first treatment (day 0) and after 14 days of treatment as described previously (McQuade et al., 2016a) . Briefly, the contrast agent, 0.4 mL of suspended barium sulfate (X-OPAQUE-HD, 2.5 g·mL À1 ), was administered via oral gavage. Prior to X-ray imaging, animals were trained/conditioned for oral gavage using 0.9% w/v saline (volume 0.1-0.4 mL); this was repeated at least three times for each animal with at least 24 h of rest period between each training. Radiographs of the gastrointestinal tract were obtained using a HiRay Plus Porta610HF X-ray apparatus [JOC Corp, Kanagawa, Japan; 50 kV, 0.3 milliampere second (mAs), exposure time 60 ms]. Mice were immobilized in the prone position inside a transparent plastic restraint tube with partly open front side for breathing; the tube comfortably restrains animal movement for the maximum of 1-2 min essential for successful X-ray imaging.
The training/conditioning with restraint were done by placing the restrainer into the mouse cages at least 24 h prior to the X-ray procedure. Using Fujifilm cassettes (24 × 30 cm), X-rays were captured immediately after administration of barium sulfate (T0) every 5 min for the first hour, every 10 min for the second hour, then every 20 min through to 360 min (T360). Animals were closely monitored during and after all procedures. Images were developed via a Fujifilm FCR Capsula XLII and analysed using eFilm 4.0.2 software. The rate of gastrointestinal transit was inferred from the time (in minutes) taken for barium sulfate to reach each region of the gastrointestinal tract (stomach, small intestines, caecum and large intestines), and longer transit times indicated lower rate of transit. Organ emptying was calculated as the time taken for complete barium emptying from specific gastrointestinal regions (stomach, small intestines) (Cabezos et al., 2008 (Cabezos et al., , 2010 Girón et al., 2015) .
Colonic motility experiments
The entire colon was removed from mice and set up in organbath chambers to record motor patterns in vitro (Wafai et al., 2013) . Briefly, the colon was placed into warmed (35°C), oxygenated physiological saline until the faecal pellets were expelled. The empty colon was cannulated at both ends and arranged horizontally in organ-bath chambers. The proximal end of the colon was connected to a reservoir containing oxygenated physiological saline to maintain intraluminal pressure. The distal end was attached to an outflow tube that provided a maximum of 2 cm H 2 O back-pressure. Organ baths were continuously superfused with oxygenated physiological saline solution, and preparations were left to equilibrate for 30 min. Contractile activity of each segment was recorded with a Logitech Quickcam Pro camera positioned 7-8 cm above the preparation. Videos (2 × 20 min) of each test condition were captured and saved in avi format using VirtualDub software (version 1.9.11). Colonic migrating motor complexes (CMMCs) were defined as propagating contractions directed from the proximal to the distal end of the colon which travelled more than 50% of the colon length (Roberts et al., 2007 (Roberts et al., , 2008 . Contractions that propagated less than 50% of the colon length were considered to be short contractions (SCs). Another form of incomplete contraction was identified as fragmented contractions (FCs) occurring simultaneously at different parts of the colon rather than propagating over the length of the colon (McQuade et al., 2016a) . Recordings were used to construct spatiotemporal maps using in-house edge detection software (Gwynne et al., 2004) . Spatiotemporal maps plot the diameter of the colon at all points during the recording allowing contractile motor patterns to be analysed with Matlab software (version 12).
Faecal water content and colonic faecal content
The wet weight of faecal pellets was measured following 14 days in vivo oxaliplatin administration. Individual mice were placed in holding cages for a period of 15-30 min on three separate occasions throughout the day; the first five pellets expelled from every mouse at each holding time were collected and weighed immediately to determine wet pellet weight. Pellets were then dehydrated for 72 h at room temperature prior to measurement of the dry weight. Water content was calculated as the difference between the wet weight and dry weight.
Data and statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . Data were assessed using two-way ANOVA, Welch's two-tailed t-test and Student's two-tailed ttest. Analyses were performed using Graph Pad Prism (Graph Pad Software Inc., CA, USA). Data are presented as mean ± SEM. Differences between group means were considered statistically significant at P < 0.05.
Materials
Oxaliplatin was supplied by Tocris Bioscience (Bristol, UK); BGP-15 was kindly donated by N-Gene R&D, Inc. (New York, NY, USA) and nicardipine was from Sigma-Aldrich (Castle Hill, NSW, Australia).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/ BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMA-COLOGY 2017/18 (Alexander et al., 2017a,b,c) .
Results
Three vehicle control groups were used in this study: (i) sterile water (H 2 O) as the vehicle for the oxaliplatin-treated group; (ii) 10% DMSO as the vehicle for the BGP-15-treated group; and (iii) DMSO +H 2 O as the vehicle for the oxaliplatin + BGP-15-treated group. No differences were found between these vehicle-treated groups in any measured parameters.
Co-administered BGP-15 prevents oxaliplatin-induced elevation of mitochondrial superoxide and changes to mitochondrial membrane potential
To evaluate production of ROS, wholemount preparations of the myenteric plexus were probed with a fluorescent mitochondrial superoxide marker MitoSOX ™ Red M36008 (n = 5 mice per group, Figure 1A -F). MitoSOX fluorescence was increased in the myenteric plexus of oxaliplatin-treated mice compared with sham H 2 O-treated animals ( Figure 1G ). Treatment with BGP-15 alone had no effect on MitoSOX fluorescence, compared withsham DMSO-treated mice but was lower compared to oxaliplatin-treated group. When given in combination with oxaliplatin, BGP-15 significantly reduced MitoSOX fluorescence, compared with oxaliplatin-treated mice to the levels found in the sham H 2 O, sham DMSO or sham DMSO + H 2 O-treated mice ( Figure 1G ). Depletion of the inner mitochondrial membrane potential (ΔΨ) is a precursor to cytochrome c diffusion from the mitochondria and subsequently apoptosis and can be measured via fluorescence (green) of monomeric JC-10 (Figure 2A-F) . A significant increase in JC-10 fluorescence was found in the myenteric plexus of oxaliplatin-treated mice compared with sham H 2 O-treated animals ( Figure 2G ). The level of JC-10 fluorescence in myenteric neurons from BGP-15-treated mice was not different from that in sham DMSO-treated mice but was significantly lower than in oxaliplatin-treated mice ( Figure 2G ). When given together with oxaliplatin, BGP-15 significantly reduced JC-10 fluorescence, compared to oxaliplatin-treated mice, but the level of JC-10 fluorescence was higher in oxaliplatin + BGP-15-treated than in sham DMSO + H 2 O-treated mice. No significant difference in JC-10 fluorescence was found between sham H 2 O, sham DMSO and sham DMSO + H 2 O-treated mice ( Figure 2G ).
BGP-15 prevents oxaliplatin-induced PARP-2 increases
To investigate changes in the PARP-1 and PARP-2 expression, cross-sections of the colon collected at day 14 were labelled and counted within a 1 mm 2 area (Figure 3) . A strong trend was noted for an increase in PARP-1-IR cells in oxaliplatintreated mice when compared to sham H 2 O-treated mice; however, this was not found to be significant ( Figure 3A ). The number of PARP-1-IR cells in BGP-15-treated mice was significantly lower than in oxaliplatin-treated mice and was comparable to levels in sham H 2 O mice. When administered together with oxaliplatin, BGP-15 further reduced the number of PARP-1-IR cells, compared with both oxaliplatintreated mice and sham DMSO + H 2 O-treated mice ( Figure 3A) . A significant increase in the number of PARP-2-IR cells was found in oxaliplatin-treated mice, compared with sham H 2 O-treated mice ( Figure 3B ). The number of PARP-2-IR cells in BGP-15-treated mice was significantly lower than in oxaliplatin-treated mice and was comparable with that in sham H 2 O, sham DMSO and sham DMSO + H 2 O-treated mice ( Figure 3B ). When administered together with oxaliplatin, BGP-15 significantly reduced the number of PARP-2-IR cells, compared with oxaliplatin-treated mice and was comparable those in sham H 2 O, sham DMSO and sham DMSO + H 2 Otreated mice ( Figure 3B ).
BGP-15 prevents oxaliplatin-induced enteric neuronal loss and reduces the proportion of nNOS-IR neurons
To investigate changes in the total number of myenteric neurons, whole-mount preparations of the colon collected at day 14 were labelled with pan-neuronal marker anti-β tubulin III for neuronal cell counting within a 2 mm 2 area (Figure 4 A-F). Repeated in vivo administration of oxaliplatin induced significant myenteric neuronal loss when compared to sham H 2 O-treated mice ( Figure 4G ). BGP-15 treatment alone had no effect on the number of myenteric neurons when compared to sham DMSO-treated mice. However, when given in combination with oxaliplatin, BGP-15 protected against neuronal loss, with the number of neurons in the oxaliplatin + BGP-15-treated group significantly higher than in the oxaliplatin-treated group. The number of neurons in oxaliplatin + BGP-15-treated mice was comparable to sham DMSO + H 2 O treated group ( Figure 4G ). As our previous studies indicated significant changes in nNOS expression, the effects of BGP-15 co-treatment on the nNOS-IR inhibitory motor and interneurons in the myenteric plexus in the colon were analysed ( Figure 5A-F) . The proportion of nNOS-IR neurons in the myenteric plexus of the colon from oxaliplatin-treated mice was higher than that in sham H 2 O-treated mice ( Figure 5G ). The proportion of nNOS-IR neurons in BGP-15-treated mice was significantly lower than Figure 6G ). The proportion of ChAT-IR neurons in BGP-15-treated mice was significantly lower than in oxaliplatintreated mice, DMSO-treated mice and oxaliplatin + BGP15-treated mice ( Figure 6G ). When administered together with oxaliplatin, BGP-15 has no effect on the proportion of ChAT-IR neurons, compared with oxaliplatin-treated mice or sham DMSO + H 2 O-treated mice ( Figure 6G ).
Co-administration of BGP-15 with oxaliplatin alleviates oxaliplatin-induced colonic dysmotility
To investigate the effects of oxaliplatin treatment on colonic motility, colons, excised at day 14 of oxaliplatin treatment, were studied in organ bath experiments, with and without BGP-15 (Figure 7) . Analysis of spatiotemporal maps from oxaliplatin-treated mice showed a significant decrease in the total number of contractions compared to sham H 2 O-treated mice ( Figure 8A , Table 1 ). BGP-15 treatment alone did not affect the total number of contractions compared to sham DMSO-treated mice. When given in combination with oxaliplatin, BGP-15 alleviated oxaliplatin-induced inhibition of contraction, but the total number of contractions remained below the level of sham DMSO + H 2 O-treated mice ( Figure 8A , Table 1 
BGP-15 co-treatment largely restores gastrointestinal transit
Gastrointestinal transit was studied via a series of radiographic images to track barium sulfate throughout the gastrointestinal tract before treatment (day 0/control) and after six injections (day 14) (Figure 10 ). The speed of barium movement was calculated by tracing barium entry from one part of the gastrointestinal tract to the next.
Following 14 days of oxaliplatin administration, movement of barium through the caecum and colon, gastric emptying, intestinal emptying and pellet formation were significantly delayed, compared with control mice (Figure 11 A-D, Table 2 ). Treatment with BGP-15 had no effect on gastrointestinal transit speed, gastric emptying, intestinal emptying or pellet formation, compared with sham DMSO-treated mice ( Figure 11A -D, Table 2 ). When given in combination with oxaliplatin, BGP-15 treatment alleviated the delay in barium movement through the caecum and colon and significantly increased the speed of intestinal emptying and pellet formation, compared with oxaliplatin-treated mice. However, the speed of intestinal emptying was still slower compared to sham DMSO+ H 2 O-treated mice. No significant differences in the speed of barium movement through the caecum and colon, gastric emptying, intestinal emptying or pellet formation were found when comparing control, sham DMSO and DMSO+ H 2 O-treated mice ( Figure 11A -D, Table 2 ).
Effect of BGP-15 co-treatment on faecal content, colonic morphology and animal body weight
To define the clinically associated symptoms of gastrointestinal dysfunction, fresh faecal pellets were collected from all mice after 14 days of treatment and dehydrated for 72 h. Faecal water content was calculated as the difference between ( Figure 12B ). BGP-15 treatment alone had no effect on dry pellet weight compared with sham DMSO-treated mice but was higher than in oxaliplatin-treated mice. When given in combination with oxaliplatin, BGP-15 had no effect on dry pellet weight when compared with either oxaliplatin-treated or sham DMSO + H 2 O-treated mice. No significant difference in dry pellet weight was found between sham H 2 O, sham DMSO and sham DMSO + H 2 O-treated mice ( Figure 12B ). The water content of faecal pellets was significantly reduced in oxaliplatin-treated mice at day 14 when compared BGP-15 prevents oxaliplatin-induced side effects BJP with sham H 2 O-treated mice ( Figure 12C ). Treatment with BGP-15 alone had no effect on faecal water content when compared with sham DMSO-treated mice but was significantly higher than in oxaliplatin-treated mice. When given in combination with oxaliplatin, BGP-15 restored faecal water content to sham levels, compared with oxaliplatin-treated mice ( Figure 12C and little cellular infiltration ( Figure 12D ). Slight crypt distension and mucosal ulceration was observed in the colons from oxaliplatin-treated mice; however, there was no change in cellular infiltration in the mucosa ( Figure 12D) . Mucosal ulceration and a low level of cellular infiltration was observed in the colons from BGP-15-treated mice ( Figure 12D ). When given in combination with oxaliplatin, BGP-15 had no significant effects on brush border, crypt structure or cellular infiltration, compared with either sham DMSO + H 2 O or oxaliplatin-treated mice ( Figure 12D ).
The body weight of each mouse was monitored prior to and daily throughout the course of all treatments. Oxaliplatin-treated mice did not gain body weight throughout the 2 week treatment regimen and, as a consequence, had a significantly reduced body weight from day 5 to the conclusion of the treatment period in comparison to sham H 2 O-treated animals ( Figure 12E ). BGP-15 treatment alone had no significant effects on body weight compared with sham DMSO-treated mice. BGP-15-treated mice gained significantly more weight from day 4 to the conclusion of the treatment compared with oxaliplatin-treated mice ( Figure 12E ). Body weight of oxaliplatin + BGP-15-treated mice was similar to sham-treated mice throughout the treatment period and significantly different to oxaliplatin-treated group from day 10 to the conclusion of the treatment ( Figure 12E ).
Discussion
Previously, we have shown that treatment with oxaliplatin induced oxidative stress and loss of enteric neurons leading to gastrointestinal dysfunction and suggested that reduction of oxidative stress in enteric neurons may offer a promising avenue for alleviation of chemotherapy-induced gastrointestinal side effects (McQuade et al., 2016b) . In the present study, we assessed the effects of BGP-15 co-administration with oxaliplatin chemotherapy on enteric neurons and gastrointestinal functions in mice. Our data demonstrated that BGP-15 reduces oxaliplatin-induced mitochondrial superoxide production and protects against mitochondrial depolarization in colonic myenteric neurons. As a result, BGP-15 protected against myenteric neuronal loss which correlated with restored intestinal motility and transit, faecal water consistency and body weight over the treatment period.
Mitochondrial dysfunction has emerged as a key player in the pathogenesis of platinum chemotherapy-induced neuronal death and dysfunction (Podratz et al., 2011; Zheng et al., 2011; Areti et al., 2014) . Several studies of animal models suggest that mitochondrial dysfunction and axonal mitotoxicity contribute to neuropathic symptoms produced by various chemotherapeutic agents such as taxanes, Vinca alkaloids, platinum compounds and bortezomib (Jin et al., 2008; Podratz et al., 2011; Zheng et al., 2011 Zheng et al., , 2012 . Evidence Frequency (number of contractions/15 min) CMMCs 11 ± 0.9 11 ± 0.6 14 ± 1.5 2 ± 0.6* 11 ± 2.8 † 8 ± 0.9* , † SCs 10 ± 1.8 10 ± 1.1 11 ± 1.1 7 ± 0.7 9 ± 1.5 12 ± 1.0 † FCs 6 ± 1.2 6 ± 0.8 8 ± 1.7 7 ± 1.0 7 ± 1.8 6 ± 0.9
Data shown are means ± SEM; n = 5 mice per group. *P < 0.05,significantly different from sham group. † P < 0.05, significantly different from oxaliplatin-treated group.
supports involvement of mitochondria-mediated oxidative and nitrosative stress in the development of peripheral nerve damage, with morphological changes including swollen and vacuolated mitochondria evident in peripheral nerve sections of chemotherapy-treated animals (Areti et al., 2014) . Specifically, mitochondrial dysfunction is implicated in oxaliplatin-evoked neuropathic pain and sensory neuropathy, and it has been suggested that drugs targeted at improving mitochondrial function may be of use in the treatment BGP-15 prevents oxaliplatin-induced side effects BJP and prevention of chemotherapy-induced side effects . Our previous study demonstrated that oxaliplatin treatment in mice was associated with mitochondrial dysfunction and production of mitochondrial superoxide in the enteric neurons (McQuade et al., 2016b) . The mechanisms underlying oxaliplatin-induced mitochondrial dysfunction in neurons remain unknown, but oxaliplatin-induced mitochondrial and energy homeostasis dysregulation in CRC cells may be mediated via direct damage to mitochondrial DNA (mtDNA) (Gourdier et al., 2004) . Although this effect is of obvious benefit to the induction of cell death pathways in neoplastic cells, suppression of mitochondrial function and the disruption of energy homeostasis would be detrimental to somatic cells and, more specifically, to enteric neurons as we have found in the present study. Our results demonstrated that co-treatment with BGP-15 reduced levels of mitochondrial superoxide production in the myenteric plexus and increased neuronal survival. Platinum accumulation has been suggested to contribute to oxaliplatin-induced DNA damage and enteric neuropathy (Stojanovska et al., 2014) . Our recent work has shown that the total platinum concentration in longitudinal muscle and myenteric plexus preparations (LMMP) is significantly increased in oxaliplatin-treated mice when compared to sham; moreover, a significant amount of platinum was found in both the nuclear and mitochondrial fractions of the LMMP preparations (Stojanovska et al., 2016) . Increased ROS production is linked to damage to various cellular components and neuronal death (Wei et al., 2000) . Mitochondrial dysfunction, particularly at the level of the mitochondrial electron transport chain (mETC), is implicated in ROS production in oxaliplatin-induced peripheral sensory neuropathy (Joseph and Levine, 2009 ). Inhibition of mETC complexes I and III, which are involved in mitochondrial ROS production, attenuates symptoms associated with oxaliplatin-induced peripheral neuropathy (Joseph and Levine, 2009) . Furthermore, accumulation of dysfunctional mitochondria due to inefficient mitophagy, a cellular process that is required to clear damaged and dysfunctional mitochondria from the mitochondria pool via targeted cell death pathways, loss of antioxidant defence systems and accumulation of ROS have also been demonstrated in models of oxaliplatin-induced peripheral neuropathy (Melli et al., 2008; Areti et al., 2014) .
The mitochondria and mtDNA are particularly susceptible to ROS-induced oxidative damage (Yakes and Van Houten, 1997) due to the fact that mtDNA lacks introns and undergoes transcription at a high rate (Glowacki et al., 2013) . Mitochondrial enzymes are especially vulnerable to lipid peroxidation by peroxynitrite, leading to reduced ATP formation and induction of mitochondrial permeability transition via opening of the permeability transition pore, which dissipates the ΔΨ (Norenberg and Rao, 2007) . Alterations in ΔΨ result in cellular stress responses including cessation of electron transport and ATP formation, mitochondrial swelling and permeabilization of the outer mitochondrial membrane, allowing the efflux of several pro-apoptotic molecules, including cytochrome c (Zoratti and Szabò, 1995; Norenberg and Rao, 2007) . Our previous work has demonstrated a significant depolarization of the mitochondrial membrane in the myenteric plexus of oxaliplatintreated mice, as shown by increased JC-10 fluorescence (McQuade et al., 2016b) . Here, we have shown that cotreatment of BGP-15 with oxaliplatin reduced the level of monomeric JC-10 fluorescence suggesting that the ΔΨ is maintained in myenteric neurons. This was correlated with neuronal protection in BGP-15 co-treated mice.
Clinical application of BGP-15 has been investigated in a wide variety of pathological conditions and has demonstrated efficacy in preclinical studies for the treatment of Duchenne's muscular dystrophy, heart failure, cardiotoxicity, nephrotoxicity and peripheral neurotoxicity (López et al., 1997; Nanbu et al., 1997; Racz et al., 2002; Volm et al., 2002; Bardos et al., 2003; Hwang et al., 2003; Sarszegi et al., 2012) . Nevertheless, this is the first study investigating the effects of BGP-15 on chemotherapy-induced enteric neuropathy and gastrointestinal dysfunction. The wide ranging clinical efficacy of this nicotinic amidoxime derivative, BGP-15, has been attributed to its multifaceted therapeutic nature as it has PARP inhibitory and HSP72 co-induction activity as well as anti-fibrotic, anti-inflammatory and antioxidant properties (Nanbu et al., 1997; Szabados et al., 2000; Racz et al., 2002; Volm et al., 2002) . Given the complex pharmacological characteristics of BGP-15, the specific mechanism underlying its beneficial effect on enteric neurons when administered with oxaliplatin may be attributed to any one or a number of its therapeutic pathways. Here, it is possible that enteric neuroprotection in mice co-treated with BGP-15 observed in our study is due to PARP inhibition and/or HSP72 activation.
In the myenteric plexus, NO is a key neurotransmitter released by nNOS-expressing interneurons and inhibitory motor neurons supplying intestinal smooth muscle . Our previous work has demonstrated an increased proportion of nNOS-IR neurons in the myenteric plexus of the distal colon and concomitant loss of cholinergic neurons associated with colonic dysmotility in oxaliplatintreated mice (Wafai et al., 2013; McQuade et al., 2016b Gastric emptying 17 ± 1 33 ± 3 27 ± 4 65 ± 9* 53 ± 8 55 ± 11
Intestinal emptying 88 ± 2 83 ± 3 86 ± 2 155 ± 11* 90 ± 5 Kaleczyc et al., 2007) . Therefore, it is possible that variation in the proportion of nNOS-IR neurons may be due to changes in chemical coding induced by oxaliplatin treatment. BGP-15 co-treatment prevented the increase in proportion of nNOS neurons in the myenteric plexus and significantly improved colonic motor patterns in oxaliplatin-treated mice. Furthermore, BGP-15 alleviated delayed intestinal emptying in oxaliplatin-treated mice and improved gastrointestinal transit time and pellet formation. PARP inhibition is neuroprotective in models of cerebral ischaemia, Huntington's disease, diabetic neuropathy and chemotherapy-induced peripheral neuropathy (Kaundal et al., 2006; Lupachyk et al., 2011; Cardinale et al., 2015) . The results of our present study have shown that BGP-15 co-treatment reduced the number of PARP-1 and PARP-2-IR cells when compared to oxaliplatintreated mice. Although BGP-15 is yet to be investigated as a BJP treatment for gastrointestinal pathologies, our data are consistent with earlier studies of PARP inhibition in models of chemotherapy-induced peripheral neuropathy and diabetic neuropathy (Brederson et al., 2012; Ta et al., 2013) . In a rat model of diabetic sensory neuropathy, thermal hyperalgesia, mechanical hyperalgesia and tactile allodynia were associated with increased nitrotyrosine and PAR immunoreactivity in the sciatic nerve and increased superoxide formation and nitrotyrosine immunoreactivity in vasa nervorum (Ilnytska et al., 2006) . PARP inhibition alleviated abnormal sensory responses and markedly reduced PAR and nitrotyrosine abundance in sciatic nerve, as well as superoxide and nitrotyrosine formation in vasa nervorum (Ilnytska et al., 2006) . In other diabetic rat models, a significant reduction in the magnitude of NO-mediated muscle relaxation in the gastric fundus was successfully ameliorated following PARP inhibition which was attributed to improved nitrergic neurotransmission (Gibson et al., 2006) . Similarly, in animal models of chemotherapy-induced painful peripheral neuropathy, PARP inhibition successfully reduced symptoms of cisplatin and oxaliplatin-induced heat and cold hyperalgesia and mechanical allodynia in mice (Ta et al., 2013) and vincristine-induced mechanical allodynia in rats (Brederson et al., 2012) . Data presented in the current study are in line with previous findings and support the beneficial effects of BGP-15 observed at the mitochondrial level, highlighting the inhibition of PARP as a possible therapeutic mechanism. Induction of HSP72 may be a contributing mechanism to the neuroprotective capacity of BGP-15. We were unable to detect HSP72 in the current study consistent with previous work demonstrating that cisplatin does not induce Hsp72 expression (Samali and Cotter, 1996) . However, there is a strong body of evidence suggesting the importance of HSP induction in models of peripheral neuropathy and neurodegeneration (Chen et al., 2012 (Chen et al., , 2013 Urban et al., 2012) . Upregulation of HSPs has been associated with reduced neuronal apoptosis (Bienemann et al., 2008) and decreased oxidative stress in neurodegenerative disorders (Chaudhury et al., 2006) . HSP72 specifically has been shown to have neuroprotective effects that repair damaged nerves (Chen et al., 2012) . In models of diabetic neuropathy, exercise-induced HSP72 expression in the spinal cord and peripheral nerves has been found to improve symptoms of peripheral neuropathy (Chen et al., 2013) . Moreover, increased HSP72 expression in the sciatic nerve of chronic constriction injury rats has been found to ameliorate neuropathic pain (Chen et al., 2012) . Although this is the first study investigating the effects of in vivo BGP-15 administration on oxaliplatin-induced enteric neuropathy, previous works exploring oral supplementation in oxaliplatin-induced peripheral sensory neuropathy have demonstrated that oral glutamine significantly reduces the incidence and severity of peripheral neuropathy in CRC patients receiving oxaliplatin (Wang et al., 2007) . While the underlying mechanism of glutamine's neuroprotective effect is yet to be established, it has been suggested to be attributable to induction of HSPs, particularly HSP72 (Savarese et al., 2003; Wischmeyer, 2002) . Although the evidence presented above highlights HSP72 induction as a potential neuroprotectant, it must be acknowledged that elevation of HSPs has been correlated with tumour progression (Gabai et al., 2005) . Increased expression of HSP72 in particular has been associated with high invasiveness, metastasis, chemotherapeutic resistance and poor prognostic outlook (Ciocca et al., 1993; Costa et al., 1997; López et al., 1997; Nanbu et al., 1997) . In CRC, expression of HSP72 closely correlates with advanced clinical stages and positive lymph node involvement (Volm et al., 2002; Hwang et al., 2003) , suggesting that HSP72 induction may be advantageous to tumour cells during cancer progression (Gabai et al., 2005) . Therefore, the co-administration of BGP-15 with chemotherapeutic agents in a CRC model needs to be further investigated to ensure that BGP-15 does not alter the anti-cancer efficacy of chemotherapeutic agents. Similar to our findings in mouse models, chemotherapy-induced damage to the myenteric plexus has been observed in colon specimens from CRC patients (Carbone et al., 2016) . Other PARP inhibitors such as iniparab and olaparib are currently in clinical trials for the treatment of breast, ovarian and prostate cancer (Liu et al., 2005; Gelmon et al., 2011; O'Shaughnessy et al., 2011; Mateo et al., 2015) . To extrapolate the results of our present study in a mouse model of chemotherapy-induced neuropathy to humans, further studies investigating the myenteric plexus in colonic specimens from human cancer patients treated with PARP inhibitors are necessary.
Results from our previous studies revealed that oxaliplatin administration was associated with reduced faecal water content and increased colonic faecal content indicative of constipation. In the current study, BGP-15 administration attenuated these symptoms of constipation in oxaliplatin-treated mice, increasing faecal water content. Our results have shown that mild ulceration of the colon epithelium following oxaliplatin treatment was not rescued by BGP-15 co-treatment. In fact, the same mild ulceration was observed when BGP-15 was administered alone. Thus, the efficacy of BGP-15 in improving oxaliplatin-induced gut dysfunction appears to be neurally mediated rather than via restoration of the gut epithelium. BGP-15 co-treatment vastly improved animal wellbeing as demonstrated by restoration of animal bodyweight gain. Taken together, our data have correlated positive BGP-15-induced changes at the cellular level with improvements in intestinal functions and animal physiology.
In conclusion, chemotherapy-induced gastrointestinal symptoms are a serious and somewhat overlooked clinical side-effect that significantly affects the prognostic outcome of CRC patients. Utilization of cytoprotective drugs to reduce gastrointestinal complications of anti-cancer chemotherapies is essential to improving both patient quality of life and outcomes of chemotherapeutic treatment. This study is the first to demonstrate that BGP-15 co-treatment reduces oxidative stress and prevents enteric neuropathy induced by oxaliplatin treatment. Neuroprotective efficacy of BGP-15 resulted in improvements to GI motility at both levels: organ level (ex vivo colonic motility) and whole GI transit (in vivo X-ray), providing an improvement in symptoms, presenting as increased body weight gain and increased faecal water content. Thus, results of this study indicate that BGP-15 may be considered as a combination therapy with oxaliplatin to reduce treatment-related gastrointestinal side effects.
